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Abstract
Background: A feature of epithelial to mesenchymal transition (EMT) relevant to tumour dissemination is the
reorganization of actin cytoskeleton/focal contacts, influencing cellular ECM adherence and motility. This is
coupled with the transcriptional repression of E-cadherin, often mediated by Snail1, Snail2 and Zeb1/δEF1. These
genes, overexpressed in breast carcinomas, are known targets of growth factor-initiated pathways, however it is
less clear how alterations in ECM attachment cross-modulate to regulate these pathways. EGF induces EMT in
the breast cancer cell line PMC42-LA and the kinase inhibitor staurosporine (ST) induces EMT in embryonic
neural epithelial cells, with F-actin de-bundling and disruption of cell-cell adhesion, via inhibition of aPKC.
Methods: PMC42-LA cells were treated for 72 h with 10 ng/ml EGF, 40 nM ST, or both, and assessed for
expression of E-cadherin repressor genes (Snail1, Snail2, Zeb1/δEF1) and EMT-related genes by QRT-PCR,
multiplex tandem PCR (MT-PCR) and immunofluorescence +/- cycloheximide. Actin and focal contacts (paxillin)
were visualized by confocal microscopy. A public database of human breast cancers was assessed for expression
of Snail1 and Snail2 in relation to outcome.
Results: When PMC42-LA were treated with EGF, Snail2 was the principal E-cadherin repressor induced. With
ST or ST+EGF this shifted to Snail1, with more extreme EMT and Zeb1/δEF1 induction seen with ST+EGF. ST
reduced stress fibres and focal contact size rapidly and independently of gene transcription. Gene expression
analysis by MT-PCR indicated that ST repressed many genes which were induced by EGF (EGFR, CAV1, CTGF,
CYR61, CD44, S100A4) and induced genes which alter the actin cytoskeleton (NLF1, NLF2, EPHB4). Examination
of the public database of breast cancers revealed tumours exhibiting higher Snail1 expression have an increased
risk of disease-recurrence. This was not seen for Snail2, and Zeb1/δEF1 showed a reverse correlation with lower
expression values being predictive of increased risk.
Conclusion: ST in combination with EGF directed a greater EMT via actin depolymerisation and focal contact
size reduction, resulting in a loosening of cell-ECM attachment along with Snail1-Zeb1/δEF1 induction. This
appeared fundamentally different to the EGF-induced EMT, highlighting the multiple pathways which can regulate
EMT. Our findings add support for a functional role for Snail1 in invasive breast cancer.
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Breast cancer is the most common malignancy in women,
accounting for 18% of all cancers, and is the leading cause
of cancer deaths in women worldwide. Most of these
deaths are due to metastatic disease [1]. An increasingly
accepted concept is that epithelial to mesenchymal transi-
tion (EMT), which is a normal developmental program, is
an important preliminary step in metastasis [2,3].
EMT involves a range of cellular phenotypic and func-
tional changes: cell-cell adhesion is disrupted and a more
dynamic cell-matrix adhesion is enhanced, polarity and
cytoskeletal organization change, ECM molecule synthe-
sis and assembly are altered and an up-regulation of
the synthesis and activity of extracellular proteases occurs
[4-9].
An early central event in many EMTs is the downregula-
tion of the homophilic cell-cell adhesion molecule E-cad-
herin. This can be mediated by Snail family proteins
which repress E-cadherin transcription by binding the E-
box E-pal element in the E-cadherin promoter, a mecha-
nism of action shared by other E-cadherin repressors
implicated in carcinogenesis such as Zeb1/δEF1, Zeb2/
SIP1 and Twist [10-12]. Indeed, these E-cadherin repres-
sors may not be independent since transfection of Snail1
into E-cadherin positive cells induces a full EMT including
the induction of Zeb1/δEF1 [10,13-15].
The Snail1 and Snail2 genes are highly homologous, and
in certain circumstances can replace each other function-
ally. For example, the consequences of Snail2 knockdown
in avian embryonic neural crest can be avoided by trans-
fection of Snail1 [16]. However, they also have somewhat
distinct roles. Snail1 is essential for mouse gastrulation
[17,18], whereas Snail2 knockout mice are viable [19].
In embryonic EMTs, induction by growth factors is a com-
mon theme. For example, neural crest EMT follows expo-
sure of neural epithelia to FGFs, Wnts and BMP4 [20].
Several growth factors involved in EMT (EGF, HGF, IGF,
FGF and TNFα) activate PI3K and Ras via signaling
through their corresponding receptor tyrosine kinases,
which in turn activate MAPK leading directly to Snail1/2
upregulation [8,21]. Epidermal growth factor (EGF) is a
potent stimulator of EMT in several cell types, and the
EGFR has been shown to directly interact with β-catenin,
leading to the tyrosine phosphorylation of β-catenin and
disruption of cadherin-dependent junctions [22-24].
Endocytosis of E-cadherin results in the release of β-cat-
enin to act on the Wnt pathway, resulting in Snail gene
transcription and further E-cadherin repression [25]. On
the other hand, engaged E-cadherin complexes in the
intact adherens junction directly inhibit the activity of the
EGFR by inhibiting transphosphorylation of Tyr845 [26].
EGF induces EMT-like changes in the PMC42-LA breast
carcinoma cell line, shown by gene expression changes
and acquisition of motility [27], are reviewed in [28].
This is an example of the most direct scheme for EMT
coordination which involves growth factor signaling to
initiate expression of EMT transcription factors which
then control EMT motor molecules [21,29]. However,
EMT is not likely to be simply a top-down process because
there is evidence from embryonic systems that modulat-
ing cellular motor molecules such as actin (cytoskeleton),
cadherins (cell-cell adhesion) or integrins (adhesion to
the ECM) can individually create cellular instability caus-
ing or predisposing to EMT-like changes. Moreover, these
apparent EMTs may be so rapid as to preclude initiation
by gene expression [30-32]. We proposed that the altera-
tion in an embryonic epithelium or carcinoma cells of
only a few of the components of the EMT response, for
example the physical alteration of cell-cell, cell-ECM or
actin cytoskeleton by environmental signals could, by
cross-modulation, kindle more EMT elements [32]. This
could account for the coordination of the complex molec-
ular changes seen in EMT. Moreover, since irreversible
genomic changes are not involved in most steps, it could
also fit with the otherwise inexplicable redifferentiations
to form epithelia seen in some secondary metastases from
invasive tumours [33,34].
Staurosporine (ST) is a serine/threonine kinase inhibitor
that induces extremely rapid, coordinated and sustained
EMT in embryonic neural epithelial cells [31]. The mech-
anism is likely to be inhibition of atypical PKC (aPKC)
which is part of the Par-3/6-cdc42 complex at the nexus
between the cytoskeleton and elements of the cadherin
cell-cell adhesion machinery [31,35]. The result is rapid
dissociation of F-actin bundles followed by cell-cell adhe-
sion instability. It was concluded that there was a cross-
modulation between various EMT effectors [32]. How
EMT-like effects via cytoskeletal machinery such as actin
may alter signaling pathways when combined with classi-
cal EMT inducers (growth factors such as EGF or the TGFβ
family) is unknown, and this information would provide
important clues as to how cross-modulation may occur.
We have previously shown the epithelial-like human
breast carcinoma PMC42-LA subline undergoes an EMT-
like change in response to EGF treatment [27], and in
response to factors secreted by human breast carcinoma-
derived stromal cells [28,36,37]. It also undergoes EMT at
the monolayer wound edge in "scratch" assays which is
synergistic with EGF-induced EMT (M. Leigh Ackland,
unpublished observation). We sought to examine how a
combination of EMT inducers (EGF, ST), which each havePage 2 of 15
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expression of the E-cadherin repressor gene set and down-
stream EMT effectors in this breast carcinoma cell line.
Finally, we investigated an extensive public database of
human primary breast tumours for evidence of clinical
implications due to increased expression levels of E-cad-
herin repressors.
Methods
Cell culture
The cell line PMC42-LA, with epithelial characteristics was
derived from the mesenchyme-like cell line PMC42
(PMC42-ET) [27], originally derived from a pleural effu-
sion of a patient with metastatic breast carcinoma [38].
PMC42-LA were maintained at 37°C, 5% CO2 in RPMI
1640 medium (Thermo Fisher Scientific, Waltham, MA)
containing 18 mM HEPES (4- [2-hydroxyethyl]-1-pipera-
zineethanesulfonic acid) and 10% FCS (fetal calf serum,
Thermo Fisher Scientific, Waltham, MA).
Immunofluorescence microscopy
For vimentin and E-cadherin immunolocalization, cells
were grown in Terasaki-type HLA wells (Nunc, Roskilde,
Denmark), washed briefly in room temperature phos-
phate buffered saline (PBS) then fixed for 10 minutes in
4% paraformaldehyde (PFA). Cells were then washed for
3 × 10 min in PBS then blocked and permeabilized using
0.1% Triton X-100 made up in PBS containing 1% BSA
and 0.2% sodium azide. Cells were then washed 3 times
again for 10 min each in PBS, followed by the application
of primary antibodies. For visualizing focal contacts by
confocal microscopy, cells were grown on 35 mm diame-
ter dishes (tissue culture grade, Nunc, Roskilde, Den-
mark), treated with antibody to paxillin as described
above, then the base of the dish was cut out and inverted
onto a drop of Vectorshield on a 24 × 50 mm coverslip
and sealed with nail polish. Sources of all primary and
secondary antibodies and their dilutions are detailed in
Table 1. All antibodies were diluted in PBS with 1% BSA
containing 0.2% sodium azide and incubated for at least
16 h at 4°C.
Quantitative Real Time PCR (qRT-PCR)
All RNA extractions were performed using Trizol (Life
Technologies, Gaithersburg, USA) according to manufac-
turer's instructions. This was followed by removal of con-
taminating genomic DNA using DNAse I (Promega
Corporation, Sydney, Australia). The concentration and
purity of RNA was determined using spectrophotometry
(Nanodrop ND-1000 spectrophotometer, Thermo Scien-
tific, Wilmington, USA) and depending on RNA yield,
0.1–1 μg of RNA was used for cDNA synthesis. cDNA syn-
thesis was performed using superscript II reverse tran-
scriptase (Invitrogen, Melbourne, Australia) according to
manufacturer's instructions, using 10 nM dNTPs and the
RNA degradation inhibitor RNAsin (Promega Corpora-
tion, Sydney, Australia). Quantitative determination of
RNA levels of various genes was performed in triplicate
using SYBR green (Applied Biosystems, Melbourne, Aus-
tralia). The following pairs of primers (sense/antisense)
were used: L32 (housekeeping gene), 5'-CAGGGTTCGTA-
GAAGATTCAAGGG-3'/5'-GATCGCTCACAATGTTTC-
CTCCAAG-3'; E-cadherin, 5'-GGCACAGATGGTGTGATT
ACAGTCAAAA-3'/5'-GTCCCAGGCGTAGACCAAGAAA-
3'; Vimentin, 5'-GCTTCAGAGAGAGGAAGCCGAAAA-3'/
5'-TTTCCAAGCCTGACCTCACGG-3'; MMP-2, 5'-CGGC
CGCAGTGACGGAAA-3'/5'-CATCCTGGGACAGACG-
GAAG-3'; Zeb1/δEF1, 5'-GCCAATAAGCAAACGATTCTG-
3'/5'-TTTGGCTGGATCACTTTCAAG-3'; Snail1, 5'-CTGC
GGGAAGGCCTTCTCT-3'/5'-CGCCTGGCACTGGTACT-
TCTT-3'; Snail2, 5'-CGGACCCACACATTACCTTGTGTTT-
3'/5'-CACAGCAGCCAGATTCCTCATGTTT-3'; Zeb2/SIP1,
5'-GGTCCAGATCGAAGCAGCTCAAT-3'/5'-GTGACTTC-
TATGTTTGTTCACATT-3'; RT-PCR and data collection
were performed on an Applied Biosystems 5700 or 7300
analyser. All quantitations were normalized to expression
of mRNA for the human ribosomal protein L32.
Multiplex-tandem PCR (MT-PCR)
MT-PCR is a quantitative, 2-step process used to quantify
expression levels of up to 72 genes in parallel. Selected
cancer genes were pre-fabricated into Corbett Rotor discs
from AusDiagnsotics Pty. Ltd. http://www.ausdiagnos
Table 1: Antibodies and probes used for fluorescent localization.
Primary antibodies and probes
Antibody/Probe Species Source Dilution
E-cadherin (HECD1) Mouse, hybridoma supernatant Dr. Alpha Yap (Inst. Mol. Sci., University of QLD) 1:2
Vimentin (V-9) Mouse Sigma-Aldrich 1:400
Paxillin (349) Mouse BD Biosciences 1:500
Phalloidin (F-actin) Fungus Molecular Probes (Invitrogen) 1:400
Secondary antibodies
Anti-mouse: Alexa 488 Goat Molecular Probes (Invitrogen) 1:2000Page 3 of 15
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this method is provided [see Additional file 1]. MT-PCR
was carried out according to the manufacturer's instruc-
tions. The first step performs a gene specific reverse tran-
scriptase reaction followed by 15 cycles of amplification,
after which insufficient product is formed to give signifi-
cant competition between reactions in the subsequent
individual PCR. The product from this reaction is then
diluted 100 fold into individual PCR assays, each contain-
ing a single primer pair, using primers nested inside the
amplicons of the first step. A Rotor-Gene (model 3000,
Corbett) and Gene Disc Heat Sealer (Corbett) were used
and additional reagents sourced from Quantace (MT-PCR
analysis kit) through local supplier BioLine (NSW, Aus-
tralia). Cycle threshold values (Ct) were determined for
each reaction after visual inspection of melt curves for
quality assurance using Corbett Rotor Gene 6000 series
software Version 1.7 (Build 70).
Statistical Analysis of Clinical Breast Cancer Dataset
All statistical analyses were performed using GraphPad
Prism (GraphPad Software, California, USA).
Results
Staurosporine combined with EGF led to an enhanced 
EMT with a switch from Snail2 to Snail1 signalling
EGF plays an important role in the development of the
normal breast and is also a key player in the progression
of breast carcinomas, and as previously shown [27], EGF
at 10 ng/ml over 72 h can induce EMT in PMC42-LA cells.
In embryonic neural epithelial cells, ST rapidly reduced F-
actin fibres and increased G-actin, delocalised cadherin,
altered cell polarity, stimulated mesenchymal migration,
and lead to expression of the HNK-1 marker of neural
crest mesenchyme [32]. We sought here to test the actin-
modifying agent ST alone and in combination with EGF
in PMC42-LA cells.
As shown in Figure 1, 40 nM ST combined with 10 ng/ml
EGF over 3 days led to an enhanced EMT, with a more
marked increase of vimentin protein and reduction of E-
cadherin expression by immunostaining than with EGF
alone. Non-phosphorylated β-catenin stained brightly in
the nucleus in the combined treatment rather than at the
cell membrane, indicating activation of the Wnt pathway,
consistent with an EMT. Rapid (3 h) F-actin disruption
and depolymerisation was due to the ST component, as
this was not found in cells treated with EGF alone, but was
present in ST alone and in the combined treatment (Fig-
ure 1). Focal contact size was reduced by ST. This was
shown by immunostaining for the focal contact protein
paxillin (Figure 2, individual black and white images: pax-
illin, colour images: F-actin – red, combined with paxillin
in green). FAK immunostaining at focal contacts was also
visibly reduced by ST [Additional file 2]. The early actin
changes were not affected by the protein synthesis inhibi-
tor cycloheximide, consistent with post-translational
mechanisms (Figure 3). In contrast, vimentin induction
was significantly reduced by cycloheximide, suggesting de
novo production consistent with an induced EMT pro-
gram.
QRT-PCR data (Figure 4) confirmed the immunohisto-
chemical results shown in Figure 1: Vimentin and MMP-2
mRNA were upregulated, and E-cadherin mRNA down-
regulated, both to a greater degree by the combined treat-
ment. EGF alone induced vimentin, whereas ST induced
MMP-2 and repressed E-cadherin more strongly than EGF
alone (Figure 4A). These changes were largely apparent by
24 hours, and remained or increased by 72 hours. The
effect of combined EGF and ST on reducing E-cadherin
expression was not seen at 24 hours, but was prominent
at 72 hours.
Snail1 and Snail2, amongst other E-cadherin repressors
such as Zeb1/δEF1 and Zeb2/SIP1, are transcription fac-
tors which orchestrate EMT because their induction leads
to a cascade of downstream gene expression changes
which embody and reinforce the EMT phenotype. As
shown in Figure 4B, EGF almost exclusively induced
Snail2 at the early stage examined (3 h), whereas ST
induced Snail1 at this time point. When EGF and ST were
combined, at 3 h, the relative expression pattern for Snail
family genes was dominated by ST. Some Snail2 was still
expressed along with Snail1 at 3 h and 24 h, however by
72 h the expression of Snail1 predominated. Snail2 per-
sisted as the main Snail gene expressed in EGF-treated cul-
tures, and Snail1 in the ST-treated cultures. The Snail1
downstream effector gene, Zeb1/δEF1 [10] followed
Snail1 induction, being maximally induced at 72 h in all
treatments, but the expression level was greatest in those
receiving combined treatment. Increased Zeb1/δEF1 was
also seen following Snail2 induction in EGF-treated cells.
Although Zeb2/SIP1 was somewhat induced by EGF at 24
h and at 72 h, and also by ST at 72 h, it was repressed by
EGF+ST at all treatment times.
Staurosporine and EGF individually induce diverse gene 
expression profiles
The gene expression programmes induced by ST and by
EGF alone were dramatically different over the 72 h
period in PMC42-LA cells when examined by MT-PCR
(Figure 5). Genes induced early (3–6 h) by EGF alone
were AKT1, CYR61, CLDN4, CD44, CLDN1, CTGF,
KRT14, KRT7 and S100A4. Expression of the last 6 genes
in this list persisted at later timepoints (24–72 h) whereas
genes primarily induced late were CAV1, CD24, CDH5,
EGFR and LGALS1. Genes which were repressed early by
EGF included CD24, DCN, EPHB4, KRT18, NLF1, NLF2,
SPARC and WT1, with DCN, EPHB4, KRT18, SPARC andPage 4 of 15
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mainly repressed only in the later time period (24–72 h)
by EGF alone were KRT8, PAX2 and PAX6. Genes induced
early by ST differed to those induced by EGF at this time-
point. They included PAX6, DCN and EPHB4, where the
latter two genes were repressed at the early timepoints by
EGF. Genes mainly induced late by ST but repressed by
EGF at this timepoint included EPHB4, PAX2, PAX6 and
WT1. In addition, ST repressed genes early which were
induced by EGF: CLDN1, CTGF, CYR61 and more perti-
nent to the EGF signal transduction cascade, EGFR. ST
repressed this gene in the "late" grouping, along with
CTGF, CYR61 and CAV1. Overall gene changes mediated
by ST or EGF alone are summarized in Table 2.
Clinical implication of Snail1 expression in human primary 
breast tumours
This study using the PMC42-LA human breast carcinoma
cell line indicated that under the conditions studied, the
most intense EMT was related to a heightened expression
of Snail1 rather than Snail2, although both led to
increased Zeb1/δEF1 with highest Zeb1/δEF1 achieved
with a combination of both treatments. Accordingly, we
interrogated the publicly available GSE4922 dataset of
microarrays performed on primary breast cancer from a
large cohort of breast cancer patients with long-term fol-
low-up [39], for evidence of clinical implications due to
increased expression levels of these E-cadherin repressors.
As shown in Figure 6A, across the 242 patients with non-
zero disease-free survival times, we found Snail1 differen-
tially expressed in tumours from patients that remained
disease-free compared with those from patients in which
there was either a local, regional or distant disease recur-
rence event, or death from breast cancer (Mann-Whitney
test, p = 0.017). A Kaplan-Meier analysis comparing
patients with Snail1 expression values either above or
below the mean Snail1 expression value (Figure 6B)
revealed that patients with tumours exhibiting higher
Snail1 expression had a higher rate of disease recurrence
(two-tailed Gehan-Breslow-Wilcoxon test, p = 0.031). As
shown in Figure 6C, one probeset for Zeb1/δEF1 demon-
strated differential expression in regards to disease recur-
rence/death from breast cancer (Mann-Whitney test, p =
0.026). A Kaplan-Meier analysis comparing patients with
ST augments and accelerates EGF-mediated EMT in PMC42-LA cellsFigure 1
ST augments and accelerates EGF-mediated EMT in PMC42-LA cells. Immunostaining of cells treated with either 10 
ng/ml EGF, 40 nM ST or both for 72 h, Vimentin: green, DAPI (nuclei): blue, E-cadherin: green, and β-catenin images taken at 
10× magnification: scale bar = 200 μm. F-actin (red). Scale bar = 10 μM.
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mean Zeb1/δEF1 expression value (Figure 6D) revealed
that patients with tumours exhibiting lower Zeb1/δEF1
expression had a higher rate of disease recurrence (two-
tailed Gehan-Breslow-Wilcoxon test, p = 0.004). No sig-
nificant differences were seen in relation to Snail2 expres-
sion and outcome (Figure 6E and 6F).
Discussion
In this study we have shown that early Snail1 rather than
Snail2 expression led to the most pronounced EMT
response in the breast carcinoma cell line PMC42-LA. Pro-
viding further support for a contributing role for Snail1 in
invasive breast cancer, we have presented analysis from a
large cohort of breast cancer patients associating increased
Snail1 mRNA expression with increased risk of disease
recurrence. The analysis presented here, associating higher
tumoural Snail1 expression with increased risk of disease
recurrence, adds to the growing body of evidence impli-
cating Snail1 in human breast cancer progression [40-45].
While our analysis was restricted to overall levels of Snail1
mRNA, Snail1 protein has been selectively localised to the
tumour-stroma interface [46]. Snail2 did not correlate
with an increased risk of recurring disease in our analysis,
however other studies have linked Snail2 as a parameter
of disease aggressiveness in ovarian and breast cancer, and
with poor survival in colorectal cancer [43,47]. Zeb1/δEF1
is a predictor of poor prognosis of uterine cancer and is
expressed in colorectal cancer [48,49], however a statisti-
cal correlation of Zeb1/δEF1 with breast cancer progres-
sion has not been reported, despite an association of its'
histological expression with increasing breast tumour
grade [50]. We found an inverse correlation between
Zeb1/δEF1 expression and outcome, with lower levels
associating with a worse outcome. This was surprising
because we found a longer-term Zeb1/δEF1 response to
both the ST/Snail1 and EGF/Snail2 EMT pathways. One
possibility is that Zeb1/δEF1 expression may be more
strongly influenced by stromal expression, as reported by
Aigner et al [50]. While these disparate data do not pre-
clude a role for all three E-cadherin repressor genes in
breast cancer progression, perhaps in our analysis in a
subset of cells masked by the general population, Snail1
appears outstanding among the E-cadherin repressors in
terms of its clinical relevance.
ST rapidly reduces focal contact size in PMC42-LA cellsFigure 2
ST rapidly reduces focal contact size in PMC42-LA cells. Cells were treated for 3 h with 10 ng/ml EGF, 40 nM ST or 
both, fixed and immunostained for the focal contact specific protein paxillin (b+w, green in enlarged images) and F-actin (red). 
Magnification: ×63, scale bar = 10 μM.
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Blockage of new protein synthesis did not block early actin changesFigure 3
Blockage of new protein synthesis did not block early actin changes. 10 mg/ml cycloheximide did not affect early (3 h) 
loss of actin stress fibres (A) but significantly reduced vimentin induction by EGF and EGF+ST (72 h) (A, B).
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QRT-PCR of PMC42-LA cells treated for 72 h with 10 ng/ml EGF, 40 nM ST or bothFigure 4
QRT-PCR of PMC42-LA cells treated for 72 h with 10 ng/ml EGF, 40 nM ST or both. Control: untreated (A) E-cad-
herin mRNA expression plotted against increased expression of hallmark mesenchymal genes MMP-2 and vimentin. (B) Com-
parison of expression of four E-cadherin repressor genes in the treatment regime used in A. Error bar values are standard 
error. Significance was set at p </= 0.05. * symbol indicates a statistically significant difference from the control within each 
time point. In the combined treatment, ^ and # indicate statistical significance from ST and EGF individual treatments, respec-
tively, within each time point.
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prising. Snail1 and Snail2 display overlapping roles in
EMT in normal embryonic and breast development and
are upregulated to varying degrees in invasive carcinogen-
esis [41,43,51]. In human breast cancer biopsies a strong
correlation was found between Snail1 expression, reduced
E-cadherin expression and invasive grade of tumours [41-
43]. Snail1 expression has been found in infiltrating duc-
tal carcinomas associated with lymph node metastases
[41,52] and distant metastases including effusions
[43,45], and has been associated with recurrence of breast
carcinomas [44]. Snail2 expression is also associated with
the presence of tumour effusions, metastasis and recur-
rence [43,53], but is also associated with partially differ-
entiated breast cancers [45], perhaps reflective of the role
of Snail2 in the developing breast [42]. Their ability to ini-
tiate EMT depends upon their ability to repress E-cadherin
transcription and, at least for Snail1, sustain this effect
despite continual signals targeting it for degradation at the
proteasome [54]. The preferential upregulation of Snail1
in the ST and ST+EGF treated cells may reflect a specific set
of triggers which drive EMT expression in breast cancers,
in comparison to those induced with EGF alone.
Snail1 induces Zeb1/δEF1
Snail1 induction with ST and with EGF+ST declined by 72
h, however it was replaced by Zeb1/δEF1 expression,
which was induced increasingly to the longest time point,
when E-cadherin was also maximally repressed. It appears
that Zeb1/δEF1 maintains long term repression of E-cad-
herin initiated by Snail1, as suggested by others previously
[10,15]. Snail1 is sensitive to GSK-3β phosphorylation
targeting it for degradation, therefore it is highly unstable
with a half-life of approximately 25 minutes [54]. How-
ever Snail1 induces Zeb1/δEF1 in various epithelial cell
lines, and only in the cell lines where Snail1 and Zeb1/
δEF1 were co-expressed was E-cadherin expression
strongly downregulated [10]. In that study, Zeb1/δEF1was
activated by Snail1 after a lag period, and Zeb1/δEF1 acti-
vation was maintained even after Snail1 expression
declined. This has been shown functionally in the pro-
gression of breast carcinomas, where Snail1 is necessary
for initial invasion, and Zeb1/δEF1 and other E-cadherin
Table 2: Summary of gene expression changes determined by 
MT-PCR.
Treatment
Gene name EGF ST
CAV1 + -
CD24 + NC
EGFR + -
EPHB4 NC +
NLF1 NC +
NLF2 NC +
CD44 + -
CDH5 + -
CLDN1 + -
CTGF ++ --
CYR61 + -
KRT7 + -
LGALS1 + -
S100A4 + -
"+" or "-" denotes whether genes were predominantly induced or 
repressed over 72 h treatment. "NC" – no change.
MT-PCR of PMC42-LA cells treated for 3, 6, 24 or 72 h with ST or EGFFigure 5
MT-PCR of PMC42-LA cells treated for 3, 6, 24 or 72 h with ST or EGF. Expression data for a range of various genes 
with relevance to EMT are shown as fold change i.e. corrected for untreated cells at each time point for each gene.
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Statistical interrogation of the GSE4922 microarray dataset of human primary breast cancersFigure 6
Statistical interrogation of the GSE4922 microarray dataset of human primary breast cancers. Expression levels 
of Snail1 (A), Zeb1/δEF1 (C) and Snail2 (E) were compared between tumours from patients who remained disease-free and 
those from patients who had a disease-recurrence event (local, regional, distant or death from breast cancer) across the 242 
patients with a non-zero disease-free survival time in the GSE4922 microarray dataset [39]. Snail1 was expressed more highly 
in tumours from patients who had a disease-recurrence event, as determined by Mann-Whitney test (p = 0.017). Zeb1/δEF1 
was expressed more highly in tumours from patients who remained disease-free, as determined by Mann-Whitney test (p = 
0.026). Kaplan-Meier analysis of disease-free survival comparing patients with a Snail1 (B), Zeb1/δEF1 (D) or Snail2 (F) expres-
sion level above or below the mean expression level. Overall patients with an above mean Snail1 expression value had a poorer 
clinical outcome as determined by Gehan-Breslow-Wilcoxon test (p = 0.031), as did those patients with a below mean Zeb1/
δEF1 expression value as determined by Gehan-Breslow-Wilcoxon test (p = 0.004).
A B
C
D
E
F
BMC Cancer 2009, 9:235 http://www.biomedcentral.com/1471-2407/9/235repressor genes are involved in the maintenance of the
mesenchymal phenotype, including motility [15]. Our
analysis of Affymetrix expression data from 51 human
breast cancer cell lines also show Zeb1/δEF1 to correlate
most tightly with the mesenchymal/BasalB subgroup
[55]. Coupling of Snail1 and Zeb1/δEF1 induction was
also found when CCN6 (Wnt-1-induced signalling pro-
tein 3) was knocked down in mammary epithelial cells
leading to E-cadherin downregulation [56]. Such progres-
sion from Snail1 to Zeb1/δEF1 has not been reported for
Snail2 [15]. In keeping with Zeb1/δEF1 induced by Snail1
after a lag period, the conditions leading to early (3 h)
expression of Snail1 in preference to Snail2 in the current
study led to the strongest expression of Zeb1/δEF1, which
peaked at 72 h, the time point at which E-cadherin was
most repressed (Figure 3A). Interestingly, in the mesen-
chymal counterpart PMC42-ET cell line, in which the
expression of E-cadherin and several other epithelial
genes are strongly repressed, Zeb1/δEF1 mRNA expression
is ~13-fold higher than in the epithelial PMC42-LA cells
(data not shown). Combined, the results in the current
study indicate that Snail1 could mediate E-cadherin
repression in EGF+ST induced EMT in PMC42-LA cells
through Zeb1/δEF1 expression. The early increase in
Snail2 by EGF was followed by upregulation of Zeb1/
δEF1, however, this was to a lesser extent than either ST
alone or ST+EGF. It remains to be seen whether the regu-
lation of Zeb1/δEF1 involves the miR-200 family and
miR-205, recently shown to regulate TGFβ-induced EMT
of mammary and ovarian epithelial cells by targeting
Zeb1/δEF1 and SIP1, and shown to be downregulated in
regions of breast cancer specimens with E-cadherin loss.
Although somewhat upregulated by individual treatments
with EGF or ST, Zeb2/SIP1 was repressed in the combined
treatment at all timepoints (fig 4) suggesting this Zeb fam-
ily member is less likely to be involved in Snail1-driven
breast cancer EMT.
Targets of staurosporine
ST is a potent, cell-permeable broad-spectrum inhibitor of
protein kinases, inhibiting CaM kinase, MLCK (myosin
light chain kinase), PKA, PKG and PKC, the latter being
the most sensitive target (Calbiochem Inhibitor Source-
book). ST at high doses (>50 nM) induces apoptosis [57-
59] and at low doses (<50 nM) can lead to differentiation,
such as in granulosa tumour cells [60]. In the current
study, the concentration of ST used did not significantly
induce apoptosis (data not shown).
Staurosporine and EMT
We have proposed that ST-induced EMT of neural epithe-
lia was initiated rapidly due chiefly to inhibition of atypi-
cal PKC (aPKC) [61]. In other cell systems, aPKC is a
crucial component of the nexus between F-actin bundles,
Par-3/6, Cdc42 and the tight junctional complex, the lat-
ter collaborating to maintain the integrity of adjacent cad-
herin junctions. ST induced Snail1 early (3 h) in PMC42-
LA cells, coinciding with F-actin depolymerization and
the reduction of focal contact size. These cytoskeletal and
adhesive events did not require new protein synthesis, this
being consistent with functional protein modifications
due to alteration in phosphorylation. A change in focal
contact size through the alteration of actin may stimulate
rapid changes in integrin signaling. Integrin linked kinase
(ILK) is a component of focal adhesion plaques [62,63],
and has direct effects on actin modification through the
phosphorylation of cofilin, where it acts to block the
actin-severing effect of unphosphorylated cofilin [64],
and integrin stimulation triggers signaling through this
kinase [65,66]. In breast cancer cells, ILK upregulation
confers resistance to anoikis [67], increases tumour inva-
sion, and rapidly induces Snail1 [68-70]. Given the spe-
cific role ILK has in inducing the transcription of Snail1 it
is possible that ST induces Snail1 through this pathway.
Staurosporine mediated effects on ECM cellular 
attachment
A reduction in focal contact size mediated by ST may have
achieved cell-ECM loosening which is a prerequisite for
EMT [71] and hence ST when combined with EGF may
have accelerated the EMT program through this mecha-
nism. Another pathway of actin reorganization may also
have been triggered by early transcription-independent
mechanisms. EphB4 was specifically upregulated after 6 h
by ST (and repressed by EGF), a gene which re-organizes
the actin cytoskeleton to promote cell movement [72].
Additionally, NLF1 and 2, factors which have been shown
to induce genes which control cellular architecture and
ECM adherence (Rnd1 and GEM GTPase) [73], were spe-
cifically and dramatically upregulated by ST compared to
EGF (Figure 5). Promoters of the NLF genes contain NFkB
binding sites and they were found to mediate NFkB effects
in endothelial cells treated with proinflammatory
cytokines IL1B and TNFα [73].
NFkB and Zeb1/δEF1
NFkB induces Zeb1/δEF1 in EMT. Constitutive expression
of the NFkB subunit p65 specifically induced Zeb1/δEF1
and Zeb2 in the mammary cell line MCF10A, concomi-
tant with suppression E-cadherin and induction of an
EMT, and transient transfection of p65 increased tran-
scription of the Zeb1/δEF1 promoter [74]. The induction
of NLF genes mainly by ST in the current study implies the
activation of NFkB, which may have contributed to Zeb1/
δEF1 induction at 72 h in ST and ST+EGF treated PMC42-
LA (Figure 4). This pathway of NFkB- Zeb1/δEF1 induc-
tion may act to further enhance the initiated ILK-Snail1
induction pathway (described earlier), with potential
cross-induction of NFkB by ILK [75] culminating in the
late Zeb1/δEF1 induction observed in figure 4 in the com-
bined treatment.Page 11 of 15
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EGF alone promoted a specific gene profile when exam-
ined by MT-PCR (Figure 5), including an increase in
CAV1. Stimulation of epithelial cells with EGF has been
shown to result in a profound increase in the number of
caveolar structures at the plasma membrane, along with
Src-phosphorylation of CAV1 on tyrosine 14 [76], and
indeed EGF induced CAV1 mRNA in a study examining
the effect of the PPARgamma ligand rosiglitazone on
phosphorylation of the EGFR [77]. In the current study,
CTGF, its relative CRY61, (related through conserved
cysteine rich domains both with distinct roles in modulat-
ing ECM signalling) and the calcium binding protein
S100A4 were upregulated by EGF and not by ST. CTGF is
elevated in advanced stages of breast cancer, promotes
mesenchymal features in MCF-7 cells when overex-
pressed, and is an upstream inducer of S100A4, a gene
important for its positive effects on cell migration [78].
The CTGF family member, CYR61, was also specifically
upregulated by EGF, as has been demonstrated in MCF-7
cells treated with EGF [79,80]. Interestingly, the ST-repres-
sive effect on CTGF and CYR61 expression observed in the
current study was also seen in an analysis of gene expres-
sion during ST-induced neuronal differentiation of
human prostate cancer cells [81] in which ST was shown
to have a role in neuronal differentiation and inhibition
of malignancy. Only a small number of genes were regu-
lated by EGF or ST in the same manner. These were
CLDN4 (up), SPARC and WT1 (both down). While more
needs to be learnt about the roles of these downstream
effectors, the dramatically different and often opposite
profiles seen in the current study clearly illustrate that EGF
and ST are operating in two very different ways.
Conclusion
These studies highlight the importance of Snail1 in EMT
in the breast carcinoma cell line PMC42 and in the pro-
gression of breast carcinoma in vivo. The breast ductal epi-
thelium is a complex environment therefore it is unlikely
that EGF initiates or acts alone in regulating breast cancer
cell invasion. EGF may combine with other physiological
factors which alter the actin cytoskeleton, as achieved here
using ST, producing a similar cross-modulation and rapid
EMT. Indeed, epigenetic signaling from the microenviron-
ment leading to changes in cellular cytoskeletal architec-
ture has been implicated in drawing tumour cells from
dormancy to metastatic growth [82]. Further study is
needed to ascertain how this system is at work in invading
primary breast tumours.
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